Mesna

Registered South African indications:

• Reduction of toxicity in urinary passages

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients

Cautions

• Breastfeeding
• Renal impairment
• Hepatic impairment
• Elderly
• Sodium controlled diet

Forms avail. in SA and covered in this monograph: inj

Used for the treatment of

Reduction of toxicity in the urinary passages
- Caused by oxazaphosphorines 

---

Consult specialist for dosages and regimens

Not established for use in children below 16 years

Pregnancy

• FDA Pregnancy Category B

Breastfeeding

• Caution; not recommended

Renal Impairment

• Caution; no information available

Hepatic Impairment

• Caution; no information available

Elderly

• Caution; no information available

Central Nervous System Disorders

• Insomnia
• Nightmare
• Headache
• Light-headedness
• Lethargy
• Drowsiness
• Dizziness
• Paresthesia
• Hyperesthesia
• Syncope
• Hypoesthesia
• Disturbance in attention
• Malaise
• Asthenia

Cardiovascular Disorders

• Palpitations
• Tachycardia
• Flushing
• Hypotension

Respiratory Disorders

• Nasal congestion
• Cough
• Pleuritic pain
• Dry mouth
• Bronchospasm
• Dyspnea
• Laryngeal discomfort
• Epistaxis
• Respiratory distress
• Hypoxia
• Chest pain

Gastrointestinal Disorders

• Abdominal pain/colic
• Nausea and vomiting
• Diarrhoea
• Mucosal irritation
• Flatulence
• Burning pain 
• Constipation
• Gingival bleeding

Hepatobiliary Disorders

• Increased transaminases 

Genitourinary Disorders

• Dysuria
• Acute renal failure

Endocrine and Metabolic Disorders

• Decreased appetite
• Feeling of dehydration

Musculoskeletal Disorders

• Arthralgia
• Back pain
• Myalgia
• Pain in extremity
• Pain in jaw

Skin and Subcutaneous Tissue Disorders

• Rash
• Pruritus
• Hyperhidrosis
• Erythema multiforme
• Drug rash
• Ulcerations and/or bullae/blistering
• Angioedema
• Urticaria
• Burning sensation
• Erythema
• Face oedema
• Peripheral oedema 
• Infusion site reactions

Immune, Blood and Lymphatic System Disorders

• Lymphadenopathy
• Anaphylaxis
• Hypersensitivity
• Activated partial thromboplastin time prolonged
• Pyrexia
• Influenza-like illness
• Rigors

Sensory Disorders

• Conjunctivitis
• Photophobia
• Blurred vision 

No information available

• Urine output
• Hydration status

Mesa is converted to a free thiol compound in the kidney, which is then able to react chemically in the urine with toxic oxazaphosphorine metabolites, thereby reducing their toxic effects on the urinary tract during urinary excretion.

Injection (per ml) 100mg

• Uromitexan (Sanofi Aventis)